1. Scrip
  2. >>Business
  3. >>Strategy

Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm

 
• By John Davis

Teva’s planned divestment of non-core assets in order to refocus the company after a troubled first-half has started with a contraceptive device.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Although the strategy may change when Kare Schultz, the newly appointed president and CEO at Teva Pharmaceutical Industries Ltd. settles in, the company’s first divestment of a non-core women’s health asset, the intrauterine copper-releasing device, Paragard, was announced Sept. 11.

The IUD and its Buffalo, NY based manufacturing facility is to be sold to the US-based CooperSurgical Inc. for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.